A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2015
At a glance
- Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2013 Results at 4 weeks post-treatment presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 26 Apr 2013 Primary endpoint 'Sustained-virological-response-rate' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History